Zhuang H, Shi S, Yuan Z et al (2019) Bevacizumab treatment for radiation brain necrosis: mechanism, efficacy and issues. Mol Cancer 18(1):21. https://doi.org/10.1186/s12943-019-0950-1

Article  PubMed  PubMed Central  Google Scholar 

Munier S, Ginalis EE, Patel NV et al (2020) Radiation necrosis in intracranial lesions. Cureus 12(4):e7603. https://doi.org/10.7759/cureus.7603

Article  PubMed  PubMed Central  Google Scholar 

Ali FS, Arevalo O, Zorofchian S et al (2019) Cerebral radiation necrosis: incidence, pathogenesis, diagnostic challenges, and future opportunities. Curr Oncol Rep 21(8):66. https://doi.org/10.1007/s11912-019-0818-y

Article  CAS  PubMed  Google Scholar 

Rahmathulla G, Marko NF, Weil RJ (2013) Cerebral radiation necrosis: a review of the pathobiology, diagnosis and management considerations. J Clin Neurosci 20(4):485–502. https://doi.org/10.1016/j.jocn.2012.09.011

Article  PubMed  Google Scholar 

Lawrence YR, Li XA, el Naqa I et al (2010) Radiation dose-volume effects in the brain. Int J Radiat Oncol Biol Phys 76(3 Suppl):S20–S27. https://doi.org/10.1016/j.ijrobp.2009.02.091

Article  PubMed  PubMed Central  Google Scholar 

Zhang P, Cao Y, Chen S et al (2021) Combination of vinpocetine and dexamethasone alleviates cognitive impairment in nasopharyngeal carcinoma patients following radiation injury. Pharmacology 106(1–2):37–44. https://doi.org/10.1159/000506777

Article  CAS  PubMed  Google Scholar 

Jiang CL, Liu L, Li Z et al (2015) The novel strategy of glucocorticoid drug development via targeting nongenomic mechanisms. Steroids 102:27–31. https://doi.org/10.1016/j.steroids.2015.06.015

Article  CAS  PubMed  Google Scholar 

Chinot OL, Wick W, Mason W et al (2014) Bevacizumab plus radiotherapy-temozolomide for newly diagnosed glioblastoma. N Engl J Med 370(8):709–722. https://doi.org/10.1056/NEJMoa1308345

Article  CAS  PubMed  Google Scholar 

Friedman HS, Prados MD, Wen PY et al (2009) Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma. J Clin Oncol 27(28):4733–4740. https://doi.org/10.1200/JCO.2008.19.8721

Article  CAS  PubMed  Google Scholar 

Wick W, Gorlia T, Bendszus M et al (2017) Lomustine and bevacizumab in progressive glioblastoma. N Engl J Med 377(20):1954–1963. https://doi.org/10.1056/NEJMoa1707358

Article  CAS  PubMed  Google Scholar 

Yang R, Duan C, Yuan L et al (2018) Inhibitors of HIF-1alpha and CXCR4 mitigate the development of radiation necrosis in mouse brain. Int J Radiat Oncol Biol Phys 100(4):1016–1025. https://doi.org/10.1016/j.ijrobp.2017.12.257

Article  CAS  PubMed  Google Scholar 

Xu Y, Rong X, Hu W et al (2018) Bevacizumab monotherapy reduces radiation-induced brain necrosis in nasopharyngeal carcinoma patients: a randomized controlled trial. Int J Radiat Oncol Biol Phys 101(5):1087–1095. https://doi.org/10.1016/j.ijrobp.2018.04.068

Article  CAS  PubMed  Google Scholar 

Nabors LB, Portnow J, Ahluwalia M et al (2020) Central nervous system cancers, version 3.2020, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw 18(11):1537–1570. https://doi.org/10.6004/jnccn.2020.0052

Article  PubMed  Google Scholar 

Bernhardt D, Konig L, Grosu AL et al (2022) DEGRO practical guideline for central nervous system radiation necrosis part 2: treatment. Strahlenther Onkol 198(11):971–980. https://doi.org/10.1007/s00066-022-01973-8

Article  PubMed  PubMed Central  Google Scholar 

Chinese Multidisciplinary Collaboration Group of Radiation-induced Brain Injury SCPBoBaSCI (2019) Neurology branch of Chinese medical doctor assciation. Diagnoses and treatments of radiation-induced brain injury: an expert consensus. Chin J Neuromed 18(6):541–549. https://doi.org/10.3760/cma.j.issn.1671-8925.2019.06.001

Article  Google Scholar 

Gupta N, Nehra P, Chauhan AS et al (2022) Cost effectiveness of bevacizumab plus chemotherapy for the treatment of advanced and metastatic cervical cancer in India—a model-based economic analysis. Jco Glob Oncol 8:e2100355. https://doi.org/10.1200/GO.21.00355

Article  PubMed  PubMed Central  Google Scholar 

Chen Z, Zhan M, Tian F et al (2020) Cost-effectiveness analysis of the addition of bevacizumab to temozolomide therapy for the treatment of unresected glioblastoma. Oncol Lett 19(1):424–430. https://doi.org/10.3892/ol.2019.11099

Article  CAS  PubMed  Google Scholar 

(2023) Yaozhi data service provider. Drug information inquiry. https://db.yaozh.com/yaopinzhongbiao. Accessed 1 May 2023

Wan X, Zhang Y, Tan C et al (2019) First-line nivolumab plus Ipilimumab vs sunitinib for metastatic renal cell carcinoma: a cost-effectiveness analysis. JAMA Oncol 5(4):491–496. https://doi.org/10.1001/jamaoncol.2018.7086

Article  PubMed  PubMed Central  Google Scholar 

Mistry R, May JR, Suri G et al (2018) Cost-effectiveness of ribociclib plus letrozole versus palbociclib plus letrozole and letrozole monotherapy in the first-line treatment of postmenopausal women with HR+/HER2-advanced or metastatic breast cancer: a U.S. Payer perspective. J Manag Care Spec Pharm 24(6):514–523. https://doi.org/10.18553/jmcp.2018.24.6.514

Article  PubMed  Google Scholar 

Sarnes E, Crofford L, Watson M et al (2011) Incidence and US costs of corticosteroid-associated adverse events: a systematic literature review. Clin Ther 33(10):1413–1432. https://doi.org/10.1016/j.clinthera.2011.09.009

Article  PubMed  Google Scholar 

Wong W, Yim YM, Kim A et al (2018) Assessment of costs associated with adverse events in patients with cancer. PLoS ONE 13(4):e196007. https://doi.org/10.1371/journal.pone.0196007

Article  CAS  PubMed  PubMed Central  Google Scholar 

Chongqing T, Liubao P, Xiaohui Z et al (2014) Cost-utility analysis of the newly recommended adjuvant chemotherapy for resectable gastric cancer patients in the 2011 Chinese national comprehensive cancer network (NCCN) clinical practice guidelines in oncology: gastric cancer. PharmacoEconomics 32(3):235–243. https://doi.org/10.1007/s40273-013-0065-2

Article  PubMed  Google Scholar 

Weng X, Huang X, Li H et al (2020) First-line treatment with atezolizumab plus nab-paclitaxel for advanced triple-negative breast cancer: a cost-effectiveness analysis. Am J Clin Oncol 43(5):340–348. https://doi.org/10.1097/COC.0000000000000671

Article  PubMed  Google Scholar 

Gong H, Ong SC, Li F et al (2023) Cost-effectiveness analysis of sorafenib, lenvatinib, atezolizumab plus bevacizumab and sintilimab plus bevacizumab for the treatment of advanced hepatocellular carcinoma in China. Cost Eff Resour Alloc 21(1):20. https://doi.org/10.1186/s12962-023-00435-x

Article  PubMed  PubMed Central  Google Scholar 

Wu B, Tobe RG, Liu Y et al (2018) Health economic analysis of antiplatelet therapy for acute coronary syndromes in the context of five eastern asian countries. Clin Drug Investig 38(7):621–630. https://doi.org/10.1007/s40261-018-0649-x

Article  CAS  PubMed  Google Scholar 

Zhang PF, Xie D, Li Q (2020) Cost-effectiveness analysis of nivolumab in the second-line treatment for advanced esophageal squamous cell carcinoma. Future Oncol 16(17):1189–1198. https://doi.org/10.2217/fon-2019-0821

Article  CAS  PubMed  Google Scholar 

Zhu J, He W, Ye M et al (2018) Cost-effectiveness of afatinib and erlotinib as second-line treatments for advanced squamous cell carcinoma of the lung. Future Oncol 14(27):2833–2840. https://doi.org/10.2217/fon-2018-0321

Article  CAS  PubMed  Google Scholar 

Yu S, Zhang Y, Yao Y et al (2020) Migraine treatment and healthcare costs: retrospective analysis of the China health insurance research association (CHIRA) database. J Headache Pain 21(1):53. https://doi.org/10.1186/s10194-020-01117-2

Article  PubMed  PubMed Central  Google Scholar 

Wu B, Zhang S, Lin H et al (2018) Prevention of renal failure in Chinese patients with newly diagnosed type 2 diabetes: a cost-effectiveness analysis. J Diabetes Investig 9(1):152–161. https://doi.org/10.1111/jdi.12653

Article  CAS  PubMed  Google Scholar 

Jiang N, Li R, Bao J et al (2021) Incidence and disease burden of community-acquired pneumonia in southeastern China: data from integrated medical resources. Hum Vaccin Immunother 17(12):5638–5645. https://doi.org/10.1080/21645515.2021.1996151

Article  PubMed  PubMed Central  Google Scholar 

National bureau of statistics of China. Annual data. http://www.stats.gov.cn/english/Statisticaldata/AnnualData

Rabin R, de Charro F (2001) EQ-5D: a measure of health status from the EuroQol group. Ann Med 33(5):337–343. https://doi.org/10.3109/07853890109002087

Article  CAS  PubMed  Google Scholar 

Luo N, Liu G, Li M et al (2017) Estimating an EQ-5D-5L value set for China. Value Health 20(4):662–669. https://doi.org/10.1016/j.jval.2016.11.016

Article  PubMed  Google Scholar 

Lester-Coll NH, Dosoretz AP, Hayman JA et al (2016) Health state utilities for patients with brain metastases. Cureus 8(7):e667. https://doi.org/10.7759/cureus.667

Article  PubMed  PubMed Central  Goo